271 related articles for article (PubMed ID: 33420675)
1. Friend or foe: ABCG2, ABCC1 and ABCB1 expression in triple-negative breast cancer.
Nedeljković M; Tanić N; Prvanović M; Milovanović Z; Tanić N
Breast Cancer; 2021 May; 28(3):727-736. PubMed ID: 33420675
[TBL] [Abstract][Full Text] [Related]
2. ABC transporter (P-gp/ABCB1, MRP1/ABCC1, BCRP/ABCG2) expression in the developing human CNS.
Daood M; Tsai C; Ahdab-Barmada M; Watchko JF
Neuropediatrics; 2008 Aug; 39(4):211-8. PubMed ID: 19165709
[TBL] [Abstract][Full Text] [Related]
3. Voruciclib, a Potent CDK4/6 Inhibitor, Antagonizes ABCB1 and ABCG2-Mediated Multi-Drug Resistance in Cancer Cells.
Gupta P; Zhang YK; Zhang XY; Wang YJ; Lu KW; Hall T; Peng R; Yang DH; Xie N; Chen ZS
Cell Physiol Biochem; 2018; 45(4):1515-1528. PubMed ID: 29486476
[TBL] [Abstract][Full Text] [Related]
4. Dacomitinib antagonizes multidrug resistance (MDR) in cancer cells by inhibiting the efflux activity of ABCB1 and ABCG2 transporters.
Fan YF; Zhang W; Zeng L; Lei ZN; Cai CY; Gupta P; Yang DH; Cui Q; Qin ZD; Chen ZS; Trombetta LD
Cancer Lett; 2018 May; 421():186-198. PubMed ID: 29331420
[TBL] [Abstract][Full Text] [Related]
5. Jadomycins are cytotoxic to ABCB1-, ABCC1-, and ABCG2-overexpressing MCF7 breast cancer cells.
Issa ME; Hall SR; Dupuis SN; Graham CL; Jakeman DL; Goralski KB
Anticancer Drugs; 2014 Mar; 25(3):255-69. PubMed ID: 24231527
[TBL] [Abstract][Full Text] [Related]
6. Karanjin interferes with ABCB1, ABCC1, and ABCG2.
Michaelis M; Rothweiler F; Nerreter T; Sharifi M; Ghafourian T; Cinatl J
J Pharm Pharm Sci; 2014; 17(1):92-105. PubMed ID: 24735762
[TBL] [Abstract][Full Text] [Related]
7. Selonsertib (GS-4997), an ASK1 inhibitor, antagonizes multidrug resistance in ABCB1- and ABCG2-overexpressing cancer cells.
Ji N; Yang Y; Cai CY; Lei ZN; Wang JQ; Gupta P; Shukla S; Ambudkar SV; Kong D; Chen ZS
Cancer Lett; 2019 Jan; 440-441():82-93. PubMed ID: 30315846
[TBL] [Abstract][Full Text] [Related]
8. Reversal effect of FW-04-806, a macrolide dilactone compound, on multidrug resistance mediated by ABCB1 and ABCG2 in vitro and in vivo.
Zhang Z; Ma C; Li P; Wu M; Ye S; Fu L; Xu J
Cell Commun Signal; 2019 Sep; 17(1):110. PubMed ID: 31472682
[TBL] [Abstract][Full Text] [Related]
9. Dinaciclib, a cyclin-dependent kinase inhibitor, is a substrate of human ABCB1 and ABCG2 and an inhibitor of human ABCC1 in vitro.
Cihalova D; Ceckova M; Kucera R; Klimes J; Staud F
Biochem Pharmacol; 2015 Dec; 98(3):465-72. PubMed ID: 26300056
[TBL] [Abstract][Full Text] [Related]
10. Promoter methylation patterns of ABCB1, ABCC1 and ABCG2 in human cancer cell lines, multidrug-resistant cell models and tumor, tumor-adjacent and tumor-distant tissues from breast cancer patients.
Spitzwieser M; Pirker C; Koblmüller B; Pfeiler G; Hacker S; Berger W; Heffeter P; Cichna-Markl M
Oncotarget; 2016 Nov; 7(45):73347-73369. PubMed ID: 27689338
[TBL] [Abstract][Full Text] [Related]
11. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.
Dai CL; Tiwari AK; Wu CP; Su XD; Wang SR; Liu DG; Ashby CR; Huang Y; Robey RW; Liang YJ; Chen LM; Shi CJ; Ambudkar SV; Chen ZS; Fu LW
Cancer Res; 2008 Oct; 68(19):7905-14. PubMed ID: 18829547
[TBL] [Abstract][Full Text] [Related]
12. Ribociclib shows potential for pharmacokinetic drug-drug interactions being a substrate of ABCB1 and potent inhibitor of ABCB1, ABCG2 and CYP450 isoforms in vitro.
Sorf A; Hofman J; Kučera R; Staud F; Ceckova M
Biochem Pharmacol; 2018 Aug; 154():10-17. PubMed ID: 29673999
[TBL] [Abstract][Full Text] [Related]
13. Ulixertinib (BVD-523) antagonizes ABCB1- and ABCG2-mediated chemotherapeutic drug resistance.
Ji N; Yang Y; Lei ZN; Cai CY; Wang JQ; Gupta P; Xian X; Yang DH; Kong D; Chen ZS
Biochem Pharmacol; 2018 Dec; 158():274-285. PubMed ID: 30431011
[TBL] [Abstract][Full Text] [Related]
14. The FLT3 and PDGFR inhibitor crenolanib is a substrate of the multidrug resistance protein ABCB1 but does not inhibit transport function at pharmacologically relevant concentrations.
Mathias TJ; Natarajan K; Shukla S; Doshi KA; Singh ZN; Ambudkar SV; Baer MR
Invest New Drugs; 2015 Apr; 33(2):300-9. PubMed ID: 25597754
[TBL] [Abstract][Full Text] [Related]
15. Avapritinib: A Selective Inhibitor of KIT and PDGFRα that Reverses ABCB1 and ABCG2-Mediated Multidrug Resistance in Cancer Cell Lines.
Wu CP; Lusvarghi S; Wang JC; Hsiao SH; Huang YH; Hung TH; Ambudkar SV
Mol Pharm; 2019 Jul; 16(7):3040-3052. PubMed ID: 31117741
[TBL] [Abstract][Full Text] [Related]
16. High expression of ATP-binding cassette transporter ABCC11 in breast tumors is associated with aggressive subtypes and low disease-free survival.
Yamada A; Ishikawa T; Ota I; Kimura M; Shimizu D; Tanabe M; Chishima T; Sasaki T; Ichikawa Y; Morita S; Yoshiura K; Takabe K; Endo I
Breast Cancer Res Treat; 2013 Feb; 137(3):773-82. PubMed ID: 23288347
[TBL] [Abstract][Full Text] [Related]
17. IRE1α-targeting downregulates ABC transporters and overcomes drug resistance of colon cancer cells.
Gao Q; Li XX; Xu YM; Zhang JZ; Rong SD; Qin YQ; Fang J
Cancer Lett; 2020 Apr; 476():67-74. PubMed ID: 32061752
[TBL] [Abstract][Full Text] [Related]
18. Association between acquired resistance to PLX4032 (vemurafenib) and ATP-binding cassette transporter expression.
Michaelis M; Rothweiler F; Nerreter T; van Rikxoort M; Zehner R; Dirks WG; Wiese M; Cinatl J
BMC Res Notes; 2014 Oct; 7():710. PubMed ID: 25300205
[TBL] [Abstract][Full Text] [Related]
19. Alisertib shows negligible potential for perpetrating pharmacokinetic drug-drug interactions on ABCB1, ABCG2 and cytochromes P450, but acts as dual-activity resistance modulator through the inhibition of ABCC1 transporter.
Vagiannis D; Zhang Y; Budagaga Y; Novotna E; Skarka A; Kammerer S; Küpper JH; Hofman J
Toxicol Appl Pharmacol; 2022 Jan; 434():115823. PubMed ID: 34896433
[TBL] [Abstract][Full Text] [Related]
20. Derivative of 5-cyano-6-phenylpyrimidin antagonizes ABCB1- and ABCG2-mediated multidrug resistance.
Wang JQ; Wang B; Lei ZN; Teng QX; Li JY; Zhang W; Ji N; Cai CY; Ma LY; Liu HM; Chen ZS
Eur J Pharmacol; 2019 Nov; 863():172611. PubMed ID: 31476282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
